News

The FDA has advised health care practitioners and patients against using certain glucose monitoring technology, that employs a specific test strip when the patients are also receiving therapeutic

China Shenghuo has reported an increase of 2.36% in the gross profits to $5.7m for the second quarter, as against $5.6m for the same period in 2008. For

Ziopharm has reported its financial results for the quarter ended June 30, 2009. The company reported a net loss of $2.4m, or $(0.11) per share, for the second

FDA has approved DNage’s Investigational New Drug application for Prodarsan, allowing the company to initiate a clinical trial in children suffering from Cockayne Syndrome (CS). DNage is a

AGI Therapeutic (AGI) has reported that its co development/co-fund and licensing agreement with Axcan, for AGI-010, has been terminated by mutual consent. AGI-010 is the company’s bimodal modified

Ziopharm has reported that the enrollment in the palifosfamide (Zymafosk or ZIO-201) phase II trial in metastatic or unresectable soft tissue sarcoma, continues in a planned manner. Reportedly,

Shin-Etsu Chemical has completed the procedures required to make its affiliate CIRES a wholly-owned subsidiary of Shin-Etsu. Earlier in December 10, 2008, Shin-Etsu announced its plan to make

Cortex has reported a net loss of $2.7m, or $0.06 per share for the quarter ended June 30, 2009, compared to a net loss of $3.9m, or $0.08

Hard to Treat Diseases (HTDS Medical) has reported the progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis,